ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
06 déc. 2023 07h20 HE
|
ZyVersa Therapeutics
AIM2 and NLRP3 inflammasome activation leads to development of atherosclerotic lesions in diabetic mice.